AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 291 min read$AVR

L1 Capital Pty Ltd sold $3.6M of AVR (indirect holdings)

L1 Capital Pty Ltd sold 441,548 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $8.14 ($8.09–$8.19, $3.60M total) across 2 trades over 2026-07-27 to 2026-07-28.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Jul 29, 2026, 10:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

A 10% owner’s indirect open-market sale of about $3.6M is disclosed, but the filing provides no new operational, regulatory, or financial guidance for AVR.

02

Market read

Traders may monitor for follow-on selling or changes in ownership, but this disclosure alone is unlikely to drive a durable repricing.

03

What to watch

Indirect holdings and the lack of a stated reason for the sale make it hard to infer conviction; the sale window spans two days and may reflect pre-planned liquidity needs.

Relevance 6/10Novelty 4/10Timing: filed 2026-07-29, covering sales on 2026-07-27 to 2026-07-28

Background

The article is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp. (AVR).

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, sold 441,548 AVR shares in open-market trades for about $3.6M at $8.09 to $8.19.

Expected impact

Near-term impact likely muted; any move would be more about broader tape/liquidity than this single Form 4.

Evidence & confidence

The filing is a Form 4 open-market sale with no 10b5-1 plan and no accompanying company-specific news, so it is typically interpreted as diversification rather than a new catalyst.

Market effects

Sector

No clear sector read-through from a single insider sale filing.

Regional

No regional impact indicated.

Global

No global market relevance indicated.

Counterpoint

What could challenge this read

Absence of a 10b5-1 plan could be read as more discretionary selling, which some traders may interpret as bearish near-term sentiment.

Key entities

  • issuer
    Anteris Technologies Global Corp.

    Subject of the Form 4 insider transaction disclosure (AVR).

  • 10% owner
    L1 Capital Pty Ltd

    Reported indirect open-market sale of AVR shares totaling about $3.6M.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AVR insider trading history →

Related articles

AUG 12
$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

rttnews.com5 min
AUG 12
$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

proactiveinvestors.com.au4 min
AUG 11
$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

leaderpost.com6 min
AUG 11
$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

SEC EDGAR 8-K4 min
JUN 4
$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.

tickerreport.com5 min